Yeu-Chin Chen

Dr. Yeu-Chin Chen


Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2019 in Haemophilia
Verified
Journal Article
Closed access
PDF file
TLTsung‐Ying Li
Tsung‐Ying Li
YWYung‐Tsan Wu
Yung‐Tsan Wu
LCLiang‐Cheng Chen
Liang‐Cheng Chen
SCShin‐Nan Cheng
Shin‐Nan Cheng
RPRu‐Yu Pan
Ru‐Yu Pan
YCYeu-Chin Chen
Yeu-Chin Chen

8 November 2016 in Haemophilia
Verified
Journal Article
Closed access
PDF file
CCC.‐Y. Chang
C.‐Y. Chang
TLT.‐Y. Li
T.‐Y. Li
SCS.‐N. Cheng
S.‐N. Cheng
RPR.‐Y. Pan
R.‐Y. Pan
HWH.‐J. Wang
H.‐J. Wang
YCYeu-Chin Chen
Yeu-Chin Chen

18 December 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
Gili KenetGili Kenet
Gili Kenet
YCYeu-Chin Chen
Yeu-Chin Chen
GLGillian Lowe
Gillian Lowe
CPCharles Percy
Charles Percy
HTHuyen Tran
Huyen Tran
BKBenjamin Kim
Benjamin Kim
Regular prophylaxis with exogenous factor VIII (FVIII) is recommended for individuals with severe haemophilia A (HA), but standardised data are scarce. Here, we report real-world data from a global cohort. Participants were men ≥18 years old with severe HA (FVIII ≤ 1 IU/dL) receiving regular prophylaxis with FVIII. Participants provided 6 months of retrospective data and were prospectively followed for up to 12 months. Annualised bleeding rate (ABR) and FVIII utilisation and infusion rates were calculated. Differences between geographic regions were explored. Of 294 enrolled participants, 225 (76.5%) completed ≥6 months of prospective follow-up. Pre-baseline and on-study, the median (range) ABR values for treated bleeds were 2.00 (0–86.0) and 1.85 (0–37.8), respectively; the median (range) annualised FVIII utilisation rates were 3629.0 (1008.5–13541.7) and 3708.0 (1311.0–14633.4) IU/kg/year, respectively; and the median (range) annualised FVIII infusion rates were 120.0 (52.0–364.0) and 122.4 (38.0–363.8) infusions/year, respectively. The median (range) Haemo-QoL-A Total Score was 76.3 (9.4–100.0) (n = 289), ranging from 85.1 in Australia to 67.7 in South America. Physical Functioning was the most impacted Haemo-QoL-A domain in 4/6 geographic regions. Despite differences among sites, participants reported bleeding requiring treatment and impaired physical functioning. These real-world data illustrate shortcomings associated with FVIII prophylaxis for this global cohort of individuals with severe HA.

30 October 2022 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
MTMin-Hua Tseng
Min-Hua Tseng
SLShih-Hua Lin
Shih-Hua Lin
JTJeng-Daw Tsai
Jeng-Daw Tsai
MWMai-Szu Wu
Mai-Szu Wu
ITI-Jung Tsai
I-Jung Tsai
CHChiu-Ching Huang
Chiu-Ching Huang
Atypical hemolytic uremic syndrome (aHUS), characterized by microangiopathic hemolytic anemia, thrombocytopenia, and acute kidney injury, is a rare but life-threatening systemic disorder caused by the dysregulation of the complement pathway. Current advances in molecular analysis and pathogenesis have facilitated the establishment of diagnosis and development of effective complement blockade. Based on this recent consensus, we provide suggestions regarding the diagnosis and management of aHUS in Taiwan. The diagnosis of aHUS is made by the presence of TMA with normal ADAMTS13 activity without known secondary causes. Although only 60% of patients with aHUS have mutations in genes involving the compliment and coagulation systems, molecular analysis is suggestive for helping establish diagnosis, clarifying the underlying pathophysiology, guiding the treatment decision-making, predicting the prognosis, and deciding renal transplantation. Complement blockade, anti-C5 monoclonal antibody, is the first-line therapy for patients with aHUS. Plasma therapy should be considered for removing autoantibody in patients with atypical HUS caused by anti-CFH or complement inhibitor is unavailable.

1 April 2019 in Journal of the Chinese Medical Association
Verified
Journal Article
Open access
CCChia-Yau Chang
Chia-Yau Chang
TLTsung-Ying Li
Tsung-Ying Li
SCShin-Nan Cheng
Shin-Nan Cheng
RPRu-Yu Pan
Ru-Yu Pan
CCChao-Neng Cheng
Chao-Neng Cheng
YCYeu-Chin Chen
Yeu-Chin Chen
The prevalence of obesity in patients with hemophilia (PWH) varies among different ethnicities, and its influence on joint bleeding and hemophilic arthropathy has not been studied in Taiwan population. We explored the prevalence and clinical correlates of obesity and the impact of body mass index (BMI) on annual joint bleeding rate (AJBR) and hemophilic arthropathy in PWH in Taiwan. We retrospectively collected clinical information on 140 severe/40 moderate PWH from 2006 to 2014. The patients’ median age was 31.5 years, ranged from 6 to 73 years. Their BMI, 6 index joints score by Pettersson scoring, AJBR, and other clinical data were analyzed. The prevalence of overweight and obesity by age group was 7.1% in PWH aged ≤10 years, and rapidly increased to 34.5% in PWH aged 11 to 18 years, 46.7% in PWH aged 18 to 29 years, 61.8% in PWH aged 30 to 39 years, 60.6% in PWH aged 40 to 49 years, and 48% in PWH aged ≥50 years, respectively. Two peak rates were 72.7% in PWH aged 35 to 44 years and 66.7% in PWH aged >65 years. Age, HCV infection, knee score, elbow score, and total 6 index joints scores were found to correlate positively with BMI. However, subtype and severity of hemophilia, ankle scores, HBV and HIV infection did not correlate with BMI. Finally, BMI was found to correlate positively with AJBR in both adult and pediatric PWH. The prevalence of overweight and obesity in adolescent and adult PWH was higher than those in the general male population in Taiwan, which rapidly increased with age to peak in PWH aged 35 to 44 years and >65 years. High index joint score, with the exception of ankle scores, positively correlated with high BMI. Further, BMI and obesity also had positive correlation with AJBR in PWH. To our knowledge, this is the first study examining these associations in PWH in Taiwan.

4 June 2011 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
YCYeu-Chin Chen
Yeu-Chin Chen
LYLuke Yang
Luke Yang
SCShin-Nan Cheng
Shin-Nan Cheng
SHShu-Hsia Hu
Shu-Hsia Hu
TCTsu-Yi Chao
Tsu-Yi Chao